Alexander Varond > Goodwin > Washington DC, United States > Lawyer Profile

Goodwin
901 NEW YORK AVENUE, NW
WASHINGTON DC 20001
DISTRICT OF COLUMBIA
United States
Alexander Varond photo

Position

Partner

Career

Alexander Varond is a partner in Goodwin’s Technology and Life Sciences groups and a co-chair of the firm’s FDA Litigation practice. Alexander advises drug, biotech, and device clients on a wide range of FDA regulatory matters. He has extensive experience in medical device and drug development, Hatch-Waxman patent and exclusivity issues, and regulatory strategy. Alexander also counsels on advertising and promotional issues, defends companies during civil and criminal investigations on a variety of issues, including off-label promotion and GMPs, and regularly advises on corporate transactions.

Prior to joining Goodwin in 2017, Alexander was a senior associate at Hyman, Phelps & McNamara, PC. His perspective is bolstered by having worked closely alongside numerous in-house regulatory and legal teams through various critical projects, including NDA preparation, formal dispute resolutions, FDA and regulatory strategy advisory meetings, and product launches.

Education

JD, 2011, The George Washington University Law School / BS, Biomedical Engineering and Management Science, 2006, University of California, San Diego

Lawyer Rankings

United States > Healthcare > Life sciences

(Next Generation Partners)

Alexander Varond – Goodwin

Goodwin’s life sciences team assist a diverse roster of pharmaceutical companies – both public and private – and life science venture capital firms. Mitchell Bloom and Kingsley Taft  jointly lead the team; Taft primarily advises life sciences companies throughout their life cycles on formation, venture financings, and IPOs, while Bloom is active in the biotechnology and medical IT spaces. Boston-based Robert Puopolo maintains a transactions focused practice, handling joint ventures and life sciences M&A. In San Francisco, Alexander Varond takes the lead on litigious matters concerning biosimilars and the Hatch-Waxman Act. Stuart Cable is particularly adept at advising on corporate governance and venture sourced investment, while Danielle Lauzon assists boards and management teams of therapeutics and bioscience companies. A large team including Philadelphia-based Rachael Bushey, who specializes in transactional and governance work in the pharma and biotech space, joined the firm from Troutman Pepper in January 2023. All named practitioners are based in Boston unless specified otherwise.